Safety of the Etonogestrel-releasing Implant During the Puerperium of Healthy Women

• Status: Completed
• Trial end date: 2008-02-01
• Target enrollment: 0
• Participant gender: Female

Summary

The purpose of this study to assess the safety of the etonogestrel-releasing subdermal implant (Implanon) inserted during the immediate puerperium of healthy women.

• Phase: N/A
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: University of Sao Paulo
• Treatments: Desogestrel; Etonogestrel; Medroxyprogesterone; Medroxyprogesterone Acetate

Criteria

Inclusion Criteria:

• age between 18 and 35 years

• Postpartum contraception desire

Exclusion Criteria:

• smoking, alcoholism or drug addiction

• presence of systemic diseases (diabetis melittus, cardiovascular disease, autoimmune diseases, liver disease, thyroid disease, or congenital renal hyperplasia)

• having a body mass index ≥ 30 kg/m2

• personal history of arterial or venous thrombosis

• using any medication that might interfere with blood coagulation or with the assessment of haemostatic and inflammatory variables

• presenting alterations in hepatic enzymes

• being allergic to local anaesthetics (xylocaine)